Document Type : Review Article
Author
MD, Endocrinology & metabolism subspecialist, Iran
Abstract
This study has systematically investigated the effect and safety of alendronate on bone density in patients with chronic kidney disease. In this study, by reviewing more than 75 articles and by searching keywords such as: Safety of alendronate, bone density, chronic kidney disease, the issue has been investigated. Alendronate tablet with the English name Alendronate is one of the well-known drugs for patients with osteoporosis and others who are exposed to this disease. Most of its users are postmenopausal women and people who have been treated with corticosteroids for any reason. The results of the present study showed that this drug slows down the activity of cells that play a role in bone decomposition. Therefore, its consumption can be effective in strengthening bones and reducing the risk of fractures, especially in the elderly. This drug does not help reduce the pain caused by a broken bone, and patients should use other treatment methods to relieve their pain. It is not known whether NSAIDs increase the need for dialysis. Therefore, the available data do not confirm the safety of NSAIDs in patients undergoing surgery. More studies involving patients with other health problems are needed. Patients with chronic kidney disease (CKD) are more at risk of developing osteoporosis (bone weakening), which can often lead to bone fractures. The results of this study showed that this drug may cause ulcers and erosions in the esophagus (the tube that connects the throat to the stomach), which can sometimes be severe. Symptoms of this condition may include heartburn, difficulty swallowing or pain when swallowing, chest pain, vomiting blood, or black or bloody stools. Tell your doctor immediately if you have these symptoms.
Keywords
Main Subjects
)